• Something wrong with this record ?

Pacemaker-Mediated Programmable Hypertension Control Therapy

P. Neuzil, B. Merkely, A. Erglis, G. Marinskis, JR. de Groot, H. Schmidinger, M. Rodriguez Venegas, M. Voskuil, T. Sturmberger, J. Petru, N. Jongejan, J. Aichinger, G. Kamzola, A. Aidietis, L. Gellér, T. Mraz, I. Osztheimer, Y. Mika, S. Evans, D....

. 2017 ; 6 (12) : . [pub] 20171223

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035457

BACKGROUND: Many patients requiring a pacemaker have persistent hypertension with systolic blood pressures above recommended levels. We evaluated a pacemaker-based Programmable Hypertension Control (PHC) therapy that uses a sequence of variably timed shorter and longer atrioventricular intervals. METHODS AND RESULTS: Patients indicated for dual-chamber pacing with office systolic blood pressure (oSBP) >150 mm Hg despite stable medical therapy were implanted with a ModeratoTM pulse generator that delivers PHC therapy. Patients were followed for 1 month (Run-In period) with conventional pacing; those with persistent oSBP >140 mm Hg were included in the study and had PHC therapy activated. The co-primary efficacy end points were changes in 24-hour ambulatory systolic blood pressure and oSBP between baseline and 3 months. Safety was assessed by tracking adverse events. Thirty-five patients met the initial inclusion criteria and underwent Moderato implantation. At 1 month, oSBP was <140 mm Hg in 7 patients who were excluded. PHC was activated in the remaining 27 patients with baseline office blood pressure 166±11/80±10 mm Hg despite an average of 3.2 antihypertensive medications. During the Run-In period, oSBP and 24-hour ambulatory systolic blood pressure decreased by 8±13 and 5±12 mm Hg (P<0.002), respectively. Compared with pre-PHC activation measurements, oSBP decreased by another 16±15 mm Hg and 24-hour ambulatory systolic blood pressure decreased by an additional 10±13 mm Hg (both P<0.01) at 3 months. No device-related serious adverse effects were noted. CONCLUSIONS: In pacemaker patients with persistent hypertension despite medical therapy, oSBP and 24-hour ambulatory systolic blood pressure are decreased by PHC therapy. Initial indications are that this therapy is a safe and promising therapy for such patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02282033.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035457
003      
CZ-PrNML
005      
20220526085828.0
007      
ta
008      
191007s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1161/JAHA.117.006974 $2 doi
035    __
$a (PubMed)29275370
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Neuzil, Petr $u Na Homolce Hospital, Prague, Czech Republic.
245    10
$a Pacemaker-Mediated Programmable Hypertension Control Therapy / $c P. Neuzil, B. Merkely, A. Erglis, G. Marinskis, JR. de Groot, H. Schmidinger, M. Rodriguez Venegas, M. Voskuil, T. Sturmberger, J. Petru, N. Jongejan, J. Aichinger, G. Kamzola, A. Aidietis, L. Gellér, T. Mraz, I. Osztheimer, Y. Mika, S. Evans, D. Burkhoff, KH. Kuck, BackBeat Study Investigators,
520    9_
$a BACKGROUND: Many patients requiring a pacemaker have persistent hypertension with systolic blood pressures above recommended levels. We evaluated a pacemaker-based Programmable Hypertension Control (PHC) therapy that uses a sequence of variably timed shorter and longer atrioventricular intervals. METHODS AND RESULTS: Patients indicated for dual-chamber pacing with office systolic blood pressure (oSBP) >150 mm Hg despite stable medical therapy were implanted with a ModeratoTM pulse generator that delivers PHC therapy. Patients were followed for 1 month (Run-In period) with conventional pacing; those with persistent oSBP >140 mm Hg were included in the study and had PHC therapy activated. The co-primary efficacy end points were changes in 24-hour ambulatory systolic blood pressure and oSBP between baseline and 3 months. Safety was assessed by tracking adverse events. Thirty-five patients met the initial inclusion criteria and underwent Moderato implantation. At 1 month, oSBP was <140 mm Hg in 7 patients who were excluded. PHC was activated in the remaining 27 patients with baseline office blood pressure 166±11/80±10 mm Hg despite an average of 3.2 antihypertensive medications. During the Run-In period, oSBP and 24-hour ambulatory systolic blood pressure decreased by 8±13 and 5±12 mm Hg (P<0.002), respectively. Compared with pre-PHC activation measurements, oSBP decreased by another 16±15 mm Hg and 24-hour ambulatory systolic blood pressure decreased by an additional 10±13 mm Hg (both P<0.01) at 3 months. No device-related serious adverse effects were noted. CONCLUSIONS: In pacemaker patients with persistent hypertension despite medical therapy, oSBP and 24-hour ambulatory systolic blood pressure are decreased by PHC therapy. Initial indications are that this therapy is a safe and promising therapy for such patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02282033.
650    _2
$a senioři $7 D000368
650    _2
$a krevní tlak $x fyziologie $7 D001794
650    _2
$a ambulantní monitorování krevního tlaku $x metody $7 D018660
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a srdeční frekvence $x fyziologie $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x patofyziologie $x terapie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    12
$a kardiostimulátor $7 D010138
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Merkely, Béla $u Heart and Vascular Center, Semmelweis University Budapest, Budapest, Hungary.
700    1_
$a Erglis, Andrejs $u Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
700    1_
$a Marinskis, Germanas $u Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.
700    1_
$a de Groot, Joris R $u Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Schmidinger, Herwig $u Abteilung für Kardiologie, AKH - Universitätsklinik für Innere Medizin II, Vienna, Austria. Sigmund Freud Private University of Vienna, Austria.
700    1_
$a Rodriguez Venegas, Manuel $u Hospital Dr. Sótero del Río, Puente Alto, Santiago, Chile.
700    1_
$a Voskuil, Michiel $u Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
700    1_
$a Sturmberger, Thomas $u Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin, Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria.
700    1_
$a Petru, Jan $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Jongejan, Niels $u Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
700    1_
$a Aichinger, Josef $u Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin, Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria.
700    1_
$a Kamzola, Ginta $u Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
700    1_
$a Aidietis, Audrius $u Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.
700    1_
$a Gellér, Laszlo $u Heart and Vascular Center, Semmelweis University Budapest, Budapest, Hungary.
700    1_
$a Mraz, Tomas $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Osztheimer, Istvan $u Heart and Vascular Center, Semmelweis University Budapest, Budapest, Hungary.
700    1_
$a Mika, Yuval $u Backbeat Medical, New Hope, PA.
700    1_
$a Evans, Steven $u Backbeat Medical, New Hope, PA.
700    1_
$a Burkhoff, Daniel $u Cardiovascular Research Foundation, New York City, NY dburkhoff@crf.org.
700    1_
$a Kuck, Karl-Heinz, $u Asklepios Klinik St. Georg, Hamburg, Germany. $d 1952- $7 xx0273250
710    2_
$a BackBeat Study Investigators
773    0_
$w MED00188127 $t Journal of the American Heart Association $x 2047-9980 $g Roč. 6, č. 12 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29275370 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20220526085822 $b ABA008
999    __
$a ok $b bmc $g 1452117 $s 1074007
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 6 $c 12 $e 20171223 $i 2047-9980 $m Journal of the American Heart Association $n J Am Heart Assoc $x MED00188127
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options